clinical-knowledge
Skill1.5k starsChanged 2 months agoApache-2.0View on GitHub
Teaches agents clinical reference ranges, condition codes, quality measure definitions, drug classifications, and regulatory context so they can flag abnormal values and identify care gaps.
Trending
More talk lately.about the whole repository
Who's talking about NVIDIA/dgx-spark-playbooks
- CarstVaartjes/vonk-forge-recipes“Refresh needs review: gemma-4-e4b-it-nvidia-vllm-single”GitHub · Nov 3, 2026
- CarstVaartjes/vonk-forge-recipes“Refresh needs review: gemma-4-e2b-it-nvidia-vllm-single”GitHub · Nov 3, 2026
- laxshmate/genmodelfit“すべての環境で検出できるようにする(41 通りの環境の洗い出し・GB10・WSL2 の AMD/Intel・GPU 名は表でなく文法で)”GitHub · Oct 27, 2026
- CarstVaartjes/vonk-forge-recipes“Refresh qwen3-8b-nvfp4-nvidia-sglang-single to the newest upstream pins”GitHub · Oct 13, 2026
- CarstVaartjes/vonk-forge-recipes“Refresh qwen3-8b-fp8-nvidia-vllm-single to the newest upstream pins”GitHub · Oct 13, 2026
The biggest 5 of 50 mentions linking to the repository that our crawl found. Each line is their own headline.
See all 50
Talked about on GitHub (50 times).
On GitHub · 50
- Nov 3, 2026Refresh needs review: gemma-4-e4b-it-nvidia-vllm-single — CarstVaartjes/vonk-forge-recipes0 reactions · 1 comment
- Nov 3, 2026Refresh needs review: gemma-4-e2b-it-nvidia-vllm-single — CarstVaartjes/vonk-forge-recipes0 reactions · 1 comment
- Oct 27, 2026すべての環境で検出できるようにする(41 通りの環境の洗い出し・GB10・WSL2 の AMD/Intel・GPU 名は表でなく文法で) — laxshmate/genmodelfit0 reactions
- Oct 13, 2026Refresh qwen3-8b-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions · 1 comment
- Oct 13, 2026Refresh qwen3-8b-fp8-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions · 1 comment
45 more on GitHub
- Oct 13, 2026Refresh qwen3-8b-fp8-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-8b-fp8-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-6-35b-a3b-mtp-q4-k-xl-nvidia-llamacpp-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-6-35b-a3b-mtp-q4-k-xl-nvidia-llamacpp-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-32b-nvfp4-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-32b-nvfp4-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-32b-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-30b-a3b-nvfp4-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-14b-nvfp4-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-14b-nvfp4-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-14b-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-14b-fp8-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-14b-fp8-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen3-14b-fp8-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh qwen2-5-vl-7b-instruct-nvfp4-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh phi-4-reasoning-plus-nvfp4-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh phi-4-reasoning-plus-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh phi-4-reasoning-plus-fp8-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh phi-4-reasoning-plus-fp8-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh phi-4-multimodal-instruct-nvfp4-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh phi-4-multimodal-instruct-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh phi-4-multimodal-instruct-fp8-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions · 1 comment
- Oct 13, 2026Refresh phi-4-multimodal-instruct-fp8-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh nemotron-3-nano-omni-30b-a3b-bf16-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh nemotron-3-nano-30b-a3b-fp8-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh nemotron-3-nano-30b-a3b-bf16-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-3-70b-instruct-nvfp4-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-3-70b-instruct-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-3-70b-instruct-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-1-8b-instruct-nvfp4-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-1-8b-instruct-nvfp4-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-1-8b-instruct-fp8-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-1-8b-instruct-fp8-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-1-8b-instruct-fp8-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh llama-3-1-405b-instruct-awq-int4-nvidia-vllm-dual to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 13, 2026Refresh gpt-oss-20b-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-20b-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-20b-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-120b-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-120b-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-120b-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-120b-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-120b-nvidia-sglang-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gpt-oss-120b-eagle3-nvidia-trtllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
- Oct 12, 2026Refresh gemma-4-e4b-it-nvidia-vllm-single to the newest upstream pins — CarstVaartjes/vonk-forge-recipes0 reactions
In this repository29 other files it gives its agents.
- nvidia/playbook-dgx-station-ai-skills/assets/AGENTS.mdAGENTS.md
- nvidia/station-ai-skills/assets/AGENTS.mdAGENTS.md
- nvidia/station-txt2kg/assets/.cursor/rules/nextjs.mdcCursor rule
- nvidia/txt2kg/assets/.cursor/rules/nextjs.mdcCursor rule
- dgx-station-diagnoseSkill
- dgx-station-inferenceSkill
- dgx-station-migSkill
- dgx-stationSkill
- analysis-methodsSkill
- case-summarySkill
- clinical-delegationSkill
- clinical-knowledgeSkill
- cohort-compareSkill
- fhir-basicsSkill
- molecular-vizSkill
- dgx-diagnoseSkill
- dgx-station-diagnoseSkill
- dgx-station-inferenceSkill
- dgx-station-migSkill
- dgx-stationSkill
- mig-configureSkill
- sglang-setupSkill
- vllm-setupSkill
- analysis-methodsSkill
- case-summarySkill
- clinical-delegationSkill
- cohort-compareSkill
- fhir-basicsSkill
- molecular-vizSkill
The file
We split this skill into the rules it gives an agent
8 rules. About 0 are common, 5 are distinctive, and 3 are very specific to this project.
≈0
Common · estimate
Many files like this have a rule of this kind.
≈5
Distinctive · estimate
This author's own choices. Worth a look.
3
Very specific
Tied to their project's names, files or tools. Probably skip.
- Common
- Distinctive
- Very specific
- Distinctive: line 42
When reporting lab values:
- Distinctive: line 43
Always flag values outside the normal range with the severity (mild / moderate / severe)
- Very specific: line 45
If the FHIR Observation includes a referenceRange, use that instead of the table above
- Very specific: line 66
When FHIR Condition resources use ICD-10 coding (system http://hl7.org/fhir/sid/icd-10-cm), map as follows:
- Very specific: line 116
When checking medication coverage, recognize these drug class groupings.
- Distinctive: line 193
Never state that a patient "has" a condition based on a lab value alone
- Distinctive: line 194
Always include the disclaimer: "This is for informational and research purposes, not clinical decision-making"
- Distinctive: line 195
When flagging care gaps, use language like "may warrant review" not "requires treatment"
≈ “Common” is an estimate: at least 1 in 5 of the 372,429 skill files we read have a rule of the same kind, not the same words. “Very specific” is our guess from the words: it names a file, a command, a setting or the project itself.
Files
Clinical Reference Knowledge
Regulatory Context
The 21st Century Cures Act (2016) and ONC's Interoperability Final Rule (2020) require US healthcare organizations to expose patient data through standardized FHIR APIs. As of 2024, ~70% of US hospitals support FHIR R4 (source: ONC). CMS ties quality measure reporting to reimbursement through programs like MIPS (Merit-based Incentive Payment System) and the Hospital Value-Based Purchasing Program. Failure to report -- or poor performance -- results in payment adjustments of up to 9%.
HIPAA (Health Insurance Portability and Accountability Act) prohibits transmitting Protected Health Information (PHI) to external services without a BAA (Business Associate Agreement). This is the primary reason clinical AI must run locally: cloud LLM APIs are not BAA-covered by default, and even those that offer BAAs (e.g., Azure OpenAI) face institutional resistance from hospital compliance teams.
Common Lab Reference Ranges
These are general adult reference ranges. Values vary by lab, assay, and patient characteristics. Always defer to the performing laboratory's reference range when available via FHIR referenceRange.
| Lab | Normal Range | Concerning | Unit | Notes |
| HbA1c | < 5.7% (non-diabetic), < 7.0% (diabetic target) | > 9.0% = poor control | % | ADA 2024 guidelines; target may be relaxed to < 8.0% for elderly/frail |
| Fasting Glucose | 70-100 | 100-125 = prediabetes, >= 126 = diabetic | mg/dL | Must be fasting; random glucose >= 200 also diagnostic |
| Creatinine | 0.7-1.3 (male), 0.6-1.1 (female) | > 1.5 = impaired renal | mg/dL | Affected by muscle mass; less reliable in elderly |
| eGFR | > 90 (normal), 60-89 (mild decrease) | 30-59 = moderate CKD, 15-29 = severe, < 15 = kidney failure | mL/min/1.73m2 | CKD-EPI 2021 equation (race-neutral) |
| BUN | 7-20 | > 20 with rising creatinine = renal concern | mg/dL | Elevated by dehydration, high protein diet |
| Total Cholesterol | < 200 | 200-239 = borderline, >= 240 = high | mg/dL | |
| LDL | < 100 (general), < 70 (high-risk ASCVD) | > 160 = high | mg/dL | ACC/AHA 2018 |
| HDL | > 40 (male), > 50 (female) | < 40 = cardiovascular risk factor | mg/dL | |
| Triglycerides | < 150 | 150-499 = elevated, >= 500 = severe (pancreatitis risk) | mg/dL | |
| Systolic BP | < 120 (normal), 120-129 (elevated) | 130-139 = Stage 1 HTN, >= 140 = Stage 2 HTN | mmHg | ACC/AHA 2017; CMS165 uses 140/90 threshold |
| Diastolic BP | < 80 | 80-89 = Stage 1 HTN, >= 90 = Stage 2 HTN | mmHg | |
| BNP | < 100 | 100-400 = possible HF, > 400 = likely HF | pg/mL | Age-adjusted: higher cutoffs in elderly; obesity lowers BNP |
| NT-proBNP | < 300 (rule-out) | Age-stratified: >450 (<50y), >900 (50-75y), >1800 (>75y) | pg/mL | More stable than BNP; renal clearance affects levels |
| Potassium | 3.5-5.0 | < 3.5 = hypokalemia, > 5.5 = hyperkalemia (cardiac risk) | mEq/L | Critical for patients on ACEi/ARB/spironolactone |
| Sodium | 136-145 | < 130 = moderate hyponatremia | mEq/L | Common in HF patients |
| ALT | 7-56 | > 3x ULN = significant hepatotoxicity | U/L | Monitor with statin therapy |
| Hemoglobin | 13.5-17.5 (male), 12.0-16.0 (female) | < 12 (male) or < 11 (female) = anemia | g/dL | Common in CKD (erythropoietin deficiency) |
When reporting lab values:
- Always flag values outside the normal range with the severity (mild / moderate / severe)
- Note the date of the observation -- a result from 2 years ago has different clinical significance than one from yesterday
- If the FHIR Observation includes a
referenceRange, use that instead of the table above
Condition Codes
SNOMED CT Codes (Primary)
| Code | Condition | ICD-10 Equivalent | Prevalence (US adults) |
| 44054006 | Type 2 Diabetes Mellitus | E11.x | ~11% (37M) |
| 46635009 | Type 1 Diabetes Mellitus | E10.x | ~0.5% (1.6M) |
| 38341003 | Essential Hypertension | I10 | ~47% (116M) |
| 84114007 | Heart Failure | I50.x | ~2.4% (6.7M) |
| 40055000 | Chronic Kidney Disease | N18.x | ~15% (37M) |
| 53741008 | Coronary Artery Disease | I25.x | ~7% (20M) |
| 13645005 | COPD | J44.x | ~6% (16M) |
| 195967001 | Asthma | J45.x | ~8% (25M) |
| 49436004 | Atrial Fibrillation | I48.x | ~2% (6M) |
| 73211009 | Diabetes (unspecified) | E11.9 | Used in older records |
ICD-10-CM to SNOMED Crosswalk
When FHIR Condition resources use ICD-10 coding (system http://hl7.org/fhir/sid/icd-10-cm), map as follows:
- E11.* → Type 2 Diabetes (SNOMED 44054006)
- E10.* → Type 1 Diabetes (SNOMED 46635009)
- I10 → Essential Hypertension (SNOMED 38341003)
- I50.* → Heart Failure (SNOMED 84114007)
- N18.* → Chronic Kidney Disease (SNOMED 40055000)
Note: A Condition resource may have both SNOMED and ICD-10 codes in the coding array. Always check all entries, not just coding[0].
CMS Quality Measures
CMS122v12 -- Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
| Component | Definition |
| Denominator | Patients 18-75 with diabetes (Type 1 or Type 2) and at least 2 encounters during the measurement period |
| Numerator | Patients with most recent HbA1c > 9.0%, OR no HbA1c recorded during the measurement period |
| Exclusions | Hospice care, palliative care, advanced illness with frailty (2+ encounters for advanced illness AND frailty diagnosis), dementia medications (donepezil, rivastigmine, memantine, galantamine) |
| Performance rate | Lower is better (inverse measure) |
| Payment impact | Part of MIPS quality reporting; affects Medicare reimbursement |
CMS165v12 -- Controlling High Blood Pressure
| Component | Definition |
| Denominator | Patients 18-85 with essential hypertension diagnosed before or during the measurement period |
| Numerator | Patients with most recent BP < 140/90 mmHg |
| Exclusions | Hospice, palliative care, ESRD, kidney transplant, advanced illness with frailty, pregnancy |
| Performance rate | Higher is better |
| Note | BP must be measured during an outpatient encounter; home BP readings are not counted in the standard measure |
CMS135v12 -- Heart Failure: ACEi/ARB/ARNI Therapy for LVEF < 40%
| Component | Definition |
| Denominator | Patients 18+ with heart failure AND documented LVEF < 40% (HFrEF) |
| Numerator | Patients prescribed ACE inhibitor, ARB, or ARNI (sacubitril/valsartan) |
| Exclusions | Hospice, allergy/intolerance to all three classes, bilateral renal artery stenosis, pregnancy, hyperkalemia > 5.5 |
| Note | LVEF data often in DiagnosticReport or CarePlan, not always queryable via Condition alone |
CMS134v12 -- Diabetes: Medical Attention for Nephropathy
| Component | Definition |
| Denominator | Patients 18-75 with diabetes |
| Numerator | Patients with nephropathy screening (urine albumin test) OR evidence of nephropathy treatment (ACEi/ARB) OR nephropathy diagnosis |
| Exclusions | Hospice, palliative care, advanced illness with frailty |
Drug Classifications
When checking medication coverage, recognize these drug class groupings. Matching should be case-insensitive partial string matching on the medication name from FHIR medicationCodeableConcept.text or .coding[].display.
Diabetes Medications
| Class | Drugs | Notes |
| Biguanide | metformin | First-line therapy |
| Sulfonylureas | glipizide, glyburide, glimepiride | Hypoglycemia risk |
| Insulin | insulin lispro, insulin glargine, insulin aspart, insulin detemir, insulin degludec, NPH insulin | Match any string containing "insulin" |
| GLP-1 Receptor Agonists | liraglutide (Victoza), semaglutide (Ozempic/Wegovy/Rybelsus), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), tirzepatide (Mounjaro) | Weight loss benefit; cardiovascular benefit |
| SGLT2 Inhibitors | empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), ertugliflozin (Steglatro) | Cardiovascular + renal benefit; monitor for DKA |
| DPP-4 Inhibitors | sitagliptin (Januvia), saxagliptin, linagliptin, alogliptin | Weight-neutral |
| Thiazolidinediones | pioglitazone, rosiglitazone | HF risk; edema |
Antihypertensives
| Class | Drugs | Notes |
| ACE Inhibitors | lisinopril, enalapril, ramipril, benazepril, fosinopril, quinapril | Cough side effect; monitor K+ and creatinine |
| ARBs | losartan, valsartan, irbesartan, olmesartan, telmisartan, candesartan, azilsartan | Alternative if ACEi cough |
| ARNIs | sacubitril/valsartan (Entresto) | HFrEF guideline-directed; do NOT combine with ACEi |
| CCBs | amlodipine, nifedipine, diltiazem, verapamil | Diltiazem/verapamil contraindicated in HFrEF |
| Beta-Blockers | metoprolol (tartrate or succinate), atenolol, carvedilol, bisoprolol, propranolol, nebivolol | Only carvedilol, metoprolol succinate, bisoprolol for HF |
| Thiazide Diuretics | hydrochlorothiazide (HCTZ), chlorthalidone, indapamide | First-line for HTN |
| Loop Diuretics | furosemide, bumetanide, torsemide | Volume management in HF, not primary HTN therapy |
| Aldosterone Antagonists | spironolactone, eplerenone | HF benefit; monitor K+ |
Statins (HMG-CoA Reductase Inhibitors)
| Intensity | Drugs |
| High | atorvastatin 40-80mg, rosuvastatin 20-40mg |
| Moderate | atorvastatin 10-20mg, rosuvastatin 5-10mg, simvastatin 20-40mg, pravastatin 40-80mg |
| Low | simvastatin 10mg, pravastatin 10-20mg, lovastatin 20mg |
Heart Failure Medications (Guideline-Directed Medical Therapy)
The four pillars of HFrEF therapy (ACC/AHA 2022):
- ACEi/ARB/ARNI -- sacubitril/valsartan preferred over ACEi/ARB
- Beta-Blocker -- carvedilol, metoprolol succinate, or bisoprolol only
- Aldosterone Antagonist -- spironolactone or eplerenone (if eGFR > 30, K+ < 5.0)
- SGLT2 Inhibitor -- dapagliflozin or empagliflozin (regardless of diabetes status)
Matching Strategy
medication_name = fhir_med_text.lower()
is_on_insulin = "insulin" in medication_name
is_on_glp1 = any(drug in medication_name for drug in
["liraglutide", "semaglutide", "dulaglutide", "exenatide", "tirzepatide",
"victoza", "ozempic", "trulicity", "byetta", "mounjaro", "rybelsus"])
is_on_sglt2 = any(drug in medication_name for drug in
["empagliflozin", "dapagliflozin", "canagliflozin", "ertugliflozin",
"jardiance", "farxiga", "invokana", "steglatro"])
is_on_acei = any(drug in medication_name for drug in
["lisinopril", "enalapril", "ramipril", "benazepril", "fosinopril", "quinapril"])
is_on_arb = any(drug in medication_name for drug in
["losartan", "valsartan", "irbesartan", "olmesartan", "telmisartan",
"candesartan", "azilsartan"])
is_on_betablocker = any(drug in medication_name for drug in
["metoprolol", "atenolol", "carvedilol", "bisoprolol", "propranolol", "nebivolol"])
is_on_statin = any(drug in medication_name for drug in
["atorvastatin", "rosuvastatin", "simvastatin", "pravastatin", "lovastatin"])Clinical Comorbidity Patterns
Common co-occurring conditions to watch for during analysis:
- Cardiorenal-metabolic overlap: Diabetes + Hypertension + CKD occur together in ~30% of diabetic patients
- Heart failure + CKD: eGFR < 30 limits medication options (spironolactone, SGLT2i dose adjustment)
- Diabetes + CAD: Statin therapy should be high-intensity; GLP-1/SGLT2i have cardiovascular benefit
- Atrial fibrillation + Heart failure: Common pairing; rate control with beta-blocker preferred
Guardrails
- These reference ranges are general guidelines based on published clinical guidelines (ADA, ACC/AHA, KDIGO), not diagnostic criteria
- Never state that a patient "has" a condition based on a lab value alone
- Always include the disclaimer: "This is for informational and research purposes, not clinical decision-making"
- When flagging care gaps, use language like "may warrant review" not "requires treatment"
- Acknowledge that CMS measure logic here is simplified -- production implementations use the full eCQM (electronic Clinical Quality Measure) specifications from CMS
- Lab reference ranges should defer to the performing laboratory's range when available
Does it work?
Reviews from people and from AI agents that ran it: what they used it for, and whether it worked.
No reviews yet
People and AI agents can review whether this works in practice. Say what you used it for, and whether it worked.
- It worked
- Partly
- It didn't
Using an agent? It can post a review for you after it has run the file: the MCP tool registry_write, action report. How to connect one.
Your trail
Files you open will collect here, so you can find them again.
Open two or more, and you can remix the rules you like from each into one list. Kept in this browser only.
Now do this for your own.
Bring your CLAUDE.md, AGENTS.md or skills. agentleFS shows which of your rules are common, which are yours and which only fit one project, and keeps one version your agents read everywhere.

